May 9, 2016 by Brian Orelli, PhDMomenta Pharmaceuticals: Waiting for Fewer InjectionsSales of Glatopa trudge along, but the big opportunity is for the three-times-a-week version of the drug.
May 5, 2016 by Brian Orelli, PhDNovo Nordisk A/S Injecting Future SalesThe diabetes-drug specialist releases earnings and shares positive clinical trial data for future growth.
May 5, 2016 by Brian Orelli, PhDBioMarin Pharmaceutical Inc.: Solid Earnings, Pipeline ProgressingThe biotech is setting itself up nicely for "break even or better on a non-GAAP basis" in 2017.
May 5, 2016 by Brian Orelli, PhDWhy Genomic Health, Inc. Earned a Higher Share PriceA solid earnings report gives the cancer-test maker's stock a boost.
May 4, 2016 by Brian Orelli, PhDTaking Inventory on Seattle Genetics, Inc. EarningsAdcetris sales didn't grow as much as hoped, but management blames an inventory drawdown and other factors while sticking with full-year guidance.
May 4, 2016 by Brian Orelli, PhDAlnylam Pharmaceuticals, Inc.'s Double-Digit "Earnings" FallThe biotech's numbers are meaningless, but an update on one of its programs sent the stock down.
May 3, 2016 by Brian Orelli, PhDQiagen NV Looks for a Strong Second HalfInvestments by the lab-test maker hurt first-quarter earnings but should pay off later in 2016.
May 3, 2016 by Brian Orelli, PhD3 Things to Watch as Genomic Health, Inc. Releases EarningsThe cancer-test maker is on the road to profitability.
Apr 29, 2016 by Brian Orelli, PhDWhy ImmunoGen, Inc. Was Down Today (Hint: It Wasn't Earnings)Investors aren't too happy about the biotech changing its clinical trial design.
Apr 28, 2016 by Brian Orelli, PhDOrkambi a 2016 Blockbuster? Vertex Pharmaceuticals Incorporated Thinks SoManagement sees Orkambi sales on track for $1 billion this year.
Apr 28, 2016 by Brian Orelli, PhDCelgene Corporation Short-Term, Long-Term Guidance Up. Medium-Term? Not So MuchFortunately the adjustment to medium-term 2017 guidance was widely expected.
Apr 28, 2016 by Brian Orelli, PhDWhy St. Jude Medical, Inc. Acquired a Higher Price TodayAbbott agrees to buy the medical-device maker.
Apr 27, 2016 by Brian Orelli, PhDBaxter International Inc's Cost-Cutting Paying OffSales of the company's healthcare products are stagnant, but earnings see a nice bump higher.
Apr 27, 2016 by Brian Orelli, PhD3 Things to Watch as Celgene Corporation Reports EarningsRevlimid will drive the revenue number, but look to the future.
Apr 26, 2016 by Brian Orelli, PhDExelixis, Inc.'s Cabometyx Approved: Let the Kidney Cancer Battle Begin!Former partners are set to battle it out in the marketplace.
Apr 22, 2016 by Brian Orelli, PhDBiogen Inc Earnings Explode Higher, Revenue Not So MuchRevenue at biotech isn't increasing as fast though.
Apr 20, 2016 by Brian Orelli, PhDNatus Medical Inc Says Adios to Venezuela GuidanceRevenue from the contract with the country becomes upside for the medical-device maker.
Apr 18, 2016 by Brian Orelli, PhD3 Things to Watch as Natus Medical Inc Reports EarningsThe revenue miss is important, but don't forget to focus on the future.
Apr 15, 2016 by Brian Orelli, PhDWhy Relypsa Inc Fell 16% TodayIs the biotech still looking to be sold?
Apr 12, 2016 by Brian Orelli, PhDWhy Horizon Pharma Shares Sank TodayShort-term-thinking investors don't like first-half guidance.
![blog-NGSSystem[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F204551%2Fblog-ngssystem1.jpg&w=384&op=resize)
![tecfidera[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F203093%2Ftecfidera1.jpg&w=384&op=resize)
![natusnewbornscreening_large1_large1_large1_large1_large[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F202756%2Fnatusnewbornscreening_large1_large1_large1_large1_large1.png&w=384&op=resize)
![packet_84_lg[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F202291%2Fpacket_84_lg1.jpg&w=384&op=resize)
![hznp-corp-hq_large[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F201894%2Fhznp-corp-hq_large1.jpg&w=384&op=resize)